Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GEH200520 + GEH200521
- Development stage
- Unknown
- Lead developer
- GE Healthcare
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
GEH200520 + GEH200521 is an investigational diagnostic agent combination developed for use in positron emission tomography (PET) imaging. The combination consists of a non-radiolabelled protein component (GEH200520) and a radiolabelled version ([18F]GEH200521), which is composed of aluminium [18F] fluoride ([18F]AlF) chelated to the RESCA-VHH protein component. This agent specifically targets CD8, a marker expressed on CD8+ T cells—a subpopulation of white blood cells involved in immune responses. The primary indication under investigation is for imaging solid tumor malignancies and monitoring immune response before and after immunotherapy treatment with immune checkpoint inhibitors. The mechanism enables visualization and quantification of CD8+ T cell infiltration in tumors using PET/CT scans, potentially aiding therapy decision-making in oncology[1][2][5].
- Other names
- [18F]GEH200521[18F]GEH200521 InjectionGEH200520 InjectionGEH-200520 InjectionGEH 200520 Injection
02
Targets
CD8A (CD8 alpha/beta Coreceptor)
Beyond the preview
Go deeper on GEH200520 + GEH200521.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GEH200520 + GEH200521.